Article
Medicine, Research & Experimental
Bing-Yan Wei, Jia-Nan Hou, Chang-Ping Yan, Shi-Yuan Wen, Xiao-Sen Shang, Yong-Chang Guo, Tao Feng, Tian-Fu Liu, Zhao-Yang Chen, Xiao-Ping Chen
Summary: The Shexiang Baoxin Pill (MUSKARDIA) promotes angiogenesis and improves cardiac function and remodeling in rats with acute myocardial infarction. This effect is mediated through the up-regulation of growth differentiation factor 15 (GDF15), which stimulates the TRPV4/calcium signaling pathway and enhances angiogenesis.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Pharmacology & Pharmacy
Hongxin Guo, Xingyuan Li, Mingjun Zhu
Summary: The efficacy and safety of Shexiang Baoxin Pill (SXBXP) for coronary slow flow (CSF) were systematically evaluated. The results showed that SXBXP combined with conventional Western medicine treatment can further improve symptoms and normalize blood indicators in CSF patients. However, the existing studies have low quality and more high-quality research is needed to confirm the efficacy and safety of this treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Mengxi Wang, Yiwen Shan, Weixin Sun, Jie Han, Huaqin Tong, Manlu Fan, Jiandong Chen, Peng Yu, Le Shen, Xiaohu Chen
Summary: This study aimed to evaluate the effects of Shexiang Baoxin Pill on coronary microvascular function. The meta-analysis of eleven studies showed that the combination of Shexiang Baoxin Pill and conventional treatment can improve coronary flow reserve (CFR), decrease microvascular resistance index (IMR), increase serum nitric oxide (NO), and reduce serum hypersensitive C-reactive protein (hs-CRP) levels. However, more high-quality clinical studies are needed to further verify the efficacy and safety of this drug.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Haixia Qin, Siyuan Li, Zhenbing Liu
Summary: The study revealed that Shexiang Baoxin Pill (SBP) has a protective effect on myocardial ischemia/reperfusion injury in patients with STEMI, improving cardiac function and decreasing myocardial infarction area.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Plant Sciences
Yong-Wei Yu, Shuai Liu, Ying-Ying Zhou, Kai-Yu Huang, Bo-Sen Wu, Zhi-Hui Lin, Chen-Xi Zhu, Yang-Jing Xue, Kang-Ting Ji
Summary: This study found that Shexiang Baoxin Pill (SBP) can inhibit pyroptosis and oxidative stress, and protect against myocardial ischemia/reperfusion injury. Additionally, it inhibits pyroptosis and improves hypoxia/reoxygenation injury by promoting autophagosome generation and accelerating autophagic flux. SBP interferes with autophagy through the interaction between mmu_circ_0005874/mmu-miR-543-3p/Map3k8.
Article
Integrative & Complementary Medicine
Jia-hui Zhao, Lei Zhang, Yang Liu, Qing-li Cheng
Summary: Shexiang Baoxin Pill (SBP) has been found to reduce inflammation in early hypertensive renal injury in rats, with a similar effect to losartan potassium.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE
(2021)
Article
Plant Sciences
Nixue Song, Dayun Lu, Gaosong Wu, Shisheng Wang, Yuanyuan Zeng, Jing Zhao, Qian Meng, Han He, Linlin Chen, Hongwen Zhu, Aijun Liu, Houkai Li, Xiaoxu Shen, Weidong Zhang, Hu Zhou
Summary: This study investigated the cardioprotective effect of Shexiang Baoxin Pill (SBP) and Suxiao Jiuxin Pill (SJP) in the treatment of acute myocardial infarction (AMI) model rats by applying serum proteomic approach. The results showed that these two traditional Chinese medicines modulate focal adhesion, platelet activation pathways to achieve their cardioprotective effects.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Plant Sciences
Feng Yu, Yue Yu, Saisai Tian, Yanting Zhou, Xiangling Chen, Ji Ye, Qian Liu, Xike Xu, Hu Zhou, Weidong Zhang
Summary: The study demonstrates that Shexiang Baoxin Pill (SBP) provides significant cardioprotective effects in myocardial infarction (MI) rats by preserving energy metabolism in cardiac tissue, particularly involving proteins related to cellular mitochondrial energy processes such as fatty acid beta-oxidation and aerobic respiration.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Yan Yang, Songtao Gao, Qiuju Fang, Mei Zhu
Summary: This study aims to evaluate the clinical efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction, with observed indexes including total effective rate of improvement of cardiac function, left ventricular ejection fraction, nitric oxide level, among others. The results will provide clinical basis for this combined therapy.
Article
Cardiac & Cardiovascular Systems
Jingjing Hu, Yongchao Zhao, Yonghui Wu, Kun Yang, Kai Hu, Aijun Sun, Junbo Ge
Summary: The study showed that SBP protects against ischemic injury in lower limbs through the ALDH2-dependent pathway, and its protective mechanism in cardiovascular microvascular endothelial cells is partly mediated through the ALDH2/AKT/mammalian target of rapamycin pathways.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2021)
Article
Integrative & Complementary Medicine
Li Yi-ping, Qiang Ting-ting, Wang Ke-yan, Wang Xiao-long
Summary: The study aimed to investigate the regulatory roles of Shexiang Baoxin Pill (SXBXW) in neointimal formation and vascular smooth muscle cells (VSMCs) invasion and apoptosis, as well as the potential molecular mechanisms. The findings reveal that SXBXW regulates proliferation, migration, and apoptosis in PDGF-BB-stimulated VSMCs through the activation of miR-451 via ATF2, p53, and Ywhaz. These results suggest that SXBXW may have potential therapeutic effects on vascular injury.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Wenyong Lin, Xin Chen, Dongyuan Wang, Ruixia Lu, Chunling Zhang, Zhenchao Niu, Jie Chen, Xiaofen Ruan, Xiaolong Wang
Summary: The mechanism of action of Shexiang Baoxin Pill (SBP) in treating cardiovascular diseases, particularly myocardial ischemia-reperfusion (I/R) injury, remains unclear. This study used heart single-nucleus and spatial RNA sequencing to explore the possible mechanism of SBP in I/R injury. Results showed that SBP improves cardiac contractility, reduces endocardial cell injury, promotes endocardial-mediated angiogenesis, and inhibits fibroblast proliferation, thereby providing cardioprotection against I/R injury.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Jingjing Wei, Teng Ma, Cheng Zhou, Pengle Hao, Bin Li, Xinlu Wang, Rui Yu, Mingjun Zhu, Yongxia Wang
Summary: This study conducted a meta-analysis to verify the therapeutic effect and safety of Shexiang Baoxin Pill (SBP) on stable coronary artery disease (SCAD). The results demonstrated that the combination therapy of SBP with conventional western medicine (CWM) was more effective in reducing major adverse cardiovascular events and improving symptoms and indicators related to angina. The evidence also showed improvements in blood lipid level and left ventricular ejection fraction after SBP treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Cell Biology
Jianbo Guo, Zongshi Qin, Qingyong He, Tung Leong Fong, Ngai Chung Lau, William C. S. Cho, Hui Zhang, Peipei Meng, Xiaoxiao Xing, Min Li, Zhang-Jin Zhang, Haiyong Chen
Summary: The study evaluated the effectiveness and safety of Shexiang Baoxin Pill (SBP) for acute myocardial infarction (AMI) and found that SBP was effective in improving clinical symptoms, cardiac function, oxidative stress, and inflammatory responses. Laboratory findings confirmed that SBP can enhance the activity of endothelial nitric oxide synthase and have adjunctive effects on AMI through antioxidative stress mechanisms.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2021)
Article
Engineering, Biomedical
Hui Xiong, Xiaoyan Liu, Zuohan Xie, Linyuan Zhu, Haipeng Lu, Cheng Wang, Jing Yao
Summary: By combining nanodrugs targeting the tumor microenvironment, this study enhances the efficacy of tumor vascular normalization treatment by inhibiting glycolysis in tumor cells and endothelial cells, leading to better antitumor effects.
ADVANCED HEALTHCARE MATERIALS
(2022)